Table 1.
Baseline characteristics of patients in the study group n = 31 (MS* patients exposed to TFL** >30 consecutive days when becoming/partner becoming pregnant and up to 2 years after discontinuation of TFL treatment), and the reference group (n = 124).
| Study group n = 31 | Reference group n = 124 | |||
|---|---|---|---|---|
| Male | Female | Male | Female | |
| N (%) | 18 (59%) | 13 (41%) | 72 (59%) | 52 (41%) |
| YEAR OF BIRTH, n | ||||
| 1965–1984 | 16 | 3 | 64 | 23 |
| 1985–2002 | 2 | 10 | 8 | 29 |
| AGE AT ONSET IN YEARS, n | ||||
| 0–24 | 4 | 6 | N/A*** | N/A |
| 25–34 | 11 | 6 | N/A | N/A |
| 35–44 | 3 | 1 | N/A | N/A |
| Mean (min;max)sd*** | 29.16 (12;38)6.76 | 25.23 (16;36)5.18 | N/A | N/A |
| AGE AT DIAGNOSIS IN YEARS, n | ||||
| 0–24 | 2 | 5 | N/A | N/A |
| 25–34 | 9 | 7 | N/A | N/A |
| 35–44 | 7 | 1 | N/A | N/A |
| Mean (min;max)sd**** | 30.72 (13;39)6.79 | 26.61 (19;37)4.91 | N/A | N/A |
*
Multiple sclerosis.
**
Teriflunomide.
***
Not applicable.
****
Standard deviation.